Functional recovery of injured cavernous nerves achieved through endogenous nerve growth factor-containing bioactive fibrous membrane
Source abstract
Abstract
Radical prostatectomy is a highly successful treatment for prostate cancer, among the most prevalent manifestations of the illness. Damage of the cavernous nerve (CN) during prostatectomy is the main cause of postoperative erectile dysfunction (ED). In this study, the capability of a personalized bioactive fibrous membrane to regenerate injured CN was investigated. The fibrous membrane bioactivity is conferred by the selectively bound nerve growth factor (NGF) present in the rat urine. In a rat model of bilateral CN crush, the implanted bioactive fibrous membrane induces CN regeneration and restoration of erectile function, showing a significantly increased number of smooth muscle cells and content of endothelial and neuronal nitric oxide synthases (eNOS; nNOS). In addition, the bioactive fibrous membrane promotes nerve regeneration by increasing the number of myelinated axons and nNOS-positive cells, therefore reversing the CN fibrosis found in untreated rats or rats treated with a bare fibrous membrane. Therefore, this personalized regenerative strategy could overcome the recognized drawbacks of currently available treatments for CN injuries. It may constitute an effective treatment for prostate cancer patients suffering from ED after being subject to radical prostatectomy. STATEMENT OF SIGNIFICANCE: The present work introduces a unique strategy to address post-surgical ED resulting from CN injury during pelvic surgery (e.g., radical prostatectomy, radical cystoprostatectomy, abdominoperineal resection). It comprises a bioactive and cell-free fibrous implant, customized to enhance CN recovery. Pre-clinical results in a rat model of bilateral CN crush demonstrated that the bioactive fibrous implant can effectively heal injured CN, and restore penile structure and function. This implant selectively binds NGF from patient fluids (i.e. urine) due to its functionalized surface and high surface area. Moreover, its local implantation reduces adverse side effects. This tailored regenerative approach has the potential to revolutionize the treatment of ED in prostate cancer patients following radical prostatectomy, overcoming current treatment limitations.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Sexual function and dysfunction studies · Urinary Bladder and Prostate Research · Urological Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (49)
Show source-provided references
1. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: A prospective, controlled, nonrandomised trial10.1016/j.eururo.2015.02.029 ↗
2. Epidemiology, staging and management of prostate cancer
3. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis10.1111/andr.12403 ↗
4. An update on emerging drugs for the treatment of erectile dysfunction10.1080/14728214.2018.1552938 ↗
5. The good, bad, and the ugly of regenerative therapies for erectile dysfunction10.21037/tau.2019.10.06 ↗
6. Platelet-rich plasma and treatment of erectile dysfunction: critical review of literature and global trends in platelet-rich plasma clinics10.1016/j.sxmr.2018.12.006 ↗
7. Can dehydrated human amnion/chorion membrane accelerate the return to potency after a nerve-sparing robotic-assisted radical prostatectomy? Propensity score-matched analysis10.1007/s11701-017-0719-8 ↗
8. Stem-cell therapy for erectile dysfunction: a review of clinical outcomes
9. Regeneration of the cavernous nerve by Sonic hedgehog using aligned peptide amphiphile nanofibers10.1016/j.biomaterials.2010.10.003 ↗
10. Brain-derived neurotrophic factor (BDNF) acts primarily via the JAK/STAT pathway to promote neurite growth in the major pelvic ganglion of the rat: part 210.1111/j.1743-6109.2006.00292.x ↗
11. 3D printed anatomical nerve regeneration pathways10.1002/adfm.201501760 ↗
12. Effect of an adipose-derived stem cell and nerve growth factor-incorporated hydrogel on recovery of erectile function in a rat model of cavernous nerve injury10.1089/ten.tea.2011.0654 ↗
13. Combined effects of brain-derived neurotrophic factor immobilized poly-lactic-co-glycolic acid membrane with human adipose-derived stem cells and basic fibroblast growth factor hydrogel on recovery of erectile dysfunction10.1089/ten.tea.2013.0495 ↗
14. Nerve growth factor modulation of the cavernous nerve response to injury10.1111/j.1743-6109.2008.01194.x ↗
15. Synergistic effect of mesenchymal stem cells infected with recombinant adenovirus expressing human BDNF on erectile function in a rat model of cavernous nerve injury10.4111/kju.2012.53.10.726 ↗
16. Activation of the NGF/TrkA signaling pathway attenuates diabetic erectile dysfunction10.18632/oncotarget.22389 ↗
17. Nerve growth factor receptor TrkA, a new receptor in insulin signaling pathway in PC12 cells10.1074/jbc.M112.436279 ↗
18. Nerve growth factor attenuates 2-deoxy-d-glucose-triggered endoplasmic reticulum stress-mediated apoptosis via enhanced expression of GRP7810.1016/j.neures.2009.09.003 ↗
19. Nerve growth factor improves functional recovery by inhibiting endoplasmic reticulum stress-induced neuronal apoptosis in rats with spinal cord injury10.1186/1479-5876-12-130 ↗
20. Neuroprotective effect of nerve growth factor loaded in porous silicon nanostructures in an alzheimer's disease model and potential delivery to the brain
21. Osteogenic induction of hBMSCs by electrospun scaffolds with dexamethasone release functionality10.1016/j.biomaterials.2010.04.010 ↗
22. Spatial immobilization of endogenous growth factors to control vascularization in bone tissue engineering10.1039/D0BM00087F ↗
23. Fibronectin bound to a fibrous substrate has chondrogenic induction properties10.1021/acs.biomac.9b01546 ↗
24. Stimulation of neurite outgrowth using autologous ngf bound at the surface of a fibrous substrate10.3390/biom12010025 ↗
25. Chondrogenesis-inductive nanofibrous substrate using both biological fluids and mesenchymal stem cells from an autologous source10.1016/j.msec.2019.01.069 ↗
26. Biofunctional nanofibrous substrate comprising immobilized antibodies and selective binding of autologous growth factors10.1021/bm500346s ↗
27. The development of a rat model of erectile dysfunction after radical prostatectomy: preliminary findings10.1111/j.1464-410X.2008.07760.x ↗
28. MicroRNA-141 binds to the nerve growth factor receptor associated protein 1 gene and restores the erectile function of diabetic rats through down-regulating the nerve growth factor/neurotrophin receptor p75 (NGF/p75NTR) signaling10.1002/jcb.28071 ↗
29. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies10.1080/01926230252824761 ↗
30. Evaluation of renal injury caused by acute volume replacement with hydroxyethyl starch 130/0.4 or Ringer's lactate solution in pigs10.4142/jvs.2018.19.5.608 ↗
31. Quality of life and satisfaction with outcome among prostate-cancer survivors10.1056/NEJMoa074311 ↗
32. Urinary nerve growth factor as a potential biomarker of treatment outcomes in overactive bladder patients10.5213/inj.1732794.397 ↗
33. Nerve growth factor levels are associated with overactive bladder symptoms and long-term treatment outcome after transurethral resection of the prostate in patients with benign prostatic hyperplasia10.1016/j.juro.2018.03.130 ↗
34. Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease
35. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders10.1016/S0929-6646(10)60133-7 ↗
36. Effect of water avoidance stress on serum and urinary NGF levels in rats: diagnostic and therapeutic implications for BPS/IC patients10.1038/s41598-019-50576-4 ↗
37. Nerve growth-factor in the urinary-bladder of the adult regulates neuronal form and function10.1172/JCI115488 ↗
38. Cavernous nerve injury using rodent animal models10.1111/j.1743-6109.2008.00955.x ↗
39. The effect of calcium channel blockers on apomorphine-induced penile erection through paraventricular nucleus of hypothalamus in the rat
40. Apomorphine-induced penile erection and yawning - site of action in brain10.1016/0006-8993(87)90272-1 ↗
41. Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary study10.1038/sj.ijir.3900621 ↗
42. Nerve growth-factor, nerve grafts and amniotic membrane grafts restore erectile function in rats10.1016/S0022-5347(17)37825-4 ↗
43. Changes in the neurogenic and endothelium-dependent relaxant responses of rabbit corpus cavernosum smooth muscle after cavernous nerve neurotomy10.1358/mf.2010.32.3.1439935 ↗
44. Differential expression of GAP-43 and neurofilament during peripheral nerve regeneration through bio-artificial conduits10.1002/term.1949 ↗
45. Physiology of penile erection and pathophysiology of erectile dysfunction10.1016/j.ucl.2005.08.007 ↗
46. Nitric-oxide release accounts for the biological-activity of endothelium-derived relaxing factor10.1038/327524a0 ↗
47. The major pelvic ganglion is the main source of nitric-oxide synthase-containing nerve-fibers in penile erectile tissue of the rat10.1016/0304-3940(93)90888-R ↗
48. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat10.1111/j.1743-6109.2008.01105.x ↗
49. Rats, neuregulins and radical prostatectomy: a conceptual overview10.3390/jcm12062208 ↗